<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi> 1 (GLP-1) is a gut-derived incretin hormone with the potential to change <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The physiological effects of GLP-1 are multiple, and many seem to ameliorate the different conditions defining the diverse physiopathology seen in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>In animal studies, GLP-1 stimulates beta-cell proliferation and neogenesis and inhibits beta-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>In humans, GLP-1 stimulates insulin secretion and inhibits glucagon and gastrointestinal secretions and motility </plain></SENT>
<SENT sid="4" pm="."><plain>It enhances satiety and reduces food intake and has beneficial effects on cardiovascular function and <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Enhancing incretin action for therapeutic use includes GLP-1 receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> resistant to degradation (incretin mimetics) and dipeptidyl peptidase (DPP)-4 inhibitors </plain></SENT>
<SENT sid="6" pm="."><plain>In clinical trials with type 2 diabetic patients on various oral <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> regimes, both treatment modalities efficaciously improve glycaemic control and beta-cell function </plain></SENT>
<SENT sid="7" pm="."><plain>Whereas the incretin mimetics induce <z:hpo ids='HP_0001824'>weight loss</z:hpo>, the DPP-4 inhibitors are considered weight neutral </plain></SENT>
<SENT sid="8" pm="."><plain>In type 1 <z:mp ids='MP_0002055'>diabetes</z:mp>, treatment with GLP-1 shows promising effects </plain></SENT>
<SENT sid="9" pm="."><plain>However, several areas need clinical confirmation: the durability of the <z:hpo ids='HP_0001824'>weight loss</z:hpo>, the ability to preserve functional beta-cell mass and the applicability in other than type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>As such, long-term studies and studies with cardiovascular end-points are needed to confirm the true benefits of these new classes of <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> drugs in the treatment of <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
</text></document>